Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NPC1 | O15118 | 1/20 | 0.52 |
| ▸ | RAB9A | P51151 | 1/20 | 0.52 |
| ▸ | MEN1 | O00255 | 5/20 | 0.48 |
| ▸ | KMT2A | Q03164 | 5/20 | 0.48 |
| ▸ | MMP2 | P08253 | 1/20 | 0.47 |
| ▸ | ANPEP | P15144 | 1/20 | 0.47 |
| ▸ | POLB | P06746 | 3/20 | 0.47 |
| ▸ | ATM | Q13315 | 1/20 | 0.44 |
| ▸ | MAPT | P10636 | 1/20 | 0.44 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.44 |
| ▸ | LMNA | P02545 | 1/20 | 0.44 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.44 |
| ▸ | GAA | P10253 | 1/20 | 0.44 |
| ▸ | EPHX1 | P07099 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL13156519 | 1.00 | NPC1 (0.52) | NPC1RAB9AMEN1KMT2AMMP2 | |
| SCHEMBL13156516 | 0.87 | L3MBTL1 (0.50) | MEN1KMT2AALDH1A1LMNA | |
| SCHEMBL3101236 | 0.87 | L3MBTL1 (0.50) | MEN1KMT2AALDH1A1LMNA | |
| SCHEMBL30583807 | 0.86 | NPC1 (0.62) | NPC1RAB9AMEN1KMT2APOLB | |
| SCHEMBL13181608 | 0.83 | HDAC3 (0.48) | NPC1RAB9AMEN1KMT2AMAPT | |
| SCHEMBL30583810 | 0.81 | NPC1 (0.56) | NPC1RAB9AMEN1KMT2AMMP2 | |
| SCHEMBL9834832 | 0.81 | NPC1 (0.53) | NPC1RAB9AMEN1KMT2APOLB | |
| SCHEMBL3103839 | 0.80 | NPC1 (0.56) | NPC1RAB9AMEN1KMT2AMAPT | |
| SCHEMBL13156495 | 0.80 | NPC1 (0.56) | NPC1RAB9AMEN1KMT2AMAPT | |
| SCHEMBL6904159 | 0.80 | NPC1 (0.59) | NPC1RAB9AMEN1KMT2AMMP2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7799934-B2 | Intermediates (synthons) in the synthesis of pharmaceuticals such as oseltamivir and other products; treating the arizidine with the nucleophile in the presence of a biaryl phosphoric acid catalyst | UNIVERSITY OF SOUTH FLORIDA (US) | 2010-09-21 | — | — | US | disclosed |
| US-20090030212-A1 | Enantioselective ring-opening of aziridines | UNIVERSITY OF SOUTH FLORIDA OF TAMPA | 2009-01-29 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090030212-A1 | Enantioselective ring-opening of aziridines | AZI2, ITPA, ADORA2A | NPC1 3406/4885RAB9A 557/4885MEN1 647/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.